BPTH
Bio-Path Holdings, Inc.
$0.04
+0.00 (+0.00%)
At close · Jul 8
Going-concern doubt
— flagged May 20, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s available cash and cash equivalents of $0.1 million at March 31, 2026 will not be sufficient to fund liquidity and capital expenditure requirements for the next 12 months from the date of issuance of these consolidated financial statements. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed May 20, 2026
Market Cap
$2.01M
Shares
50,297,451
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.04
Open$0.04
Day$0.04–0.04
52W$0.01–0.17
Avg vol 30d31K
Short int8K · 0.0% float · 1.0d
Short vol80%
Last earningsMar 28, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 20
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−35%
below
Price vs 50-day avg
−5%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
19%
mid-range
Momentum
relative strength
1-month return
+33%
trailing
6-month return
−20%
trailing
YTD return
−33%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -60.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
9
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+88%
Y/Y
Free cash flow
$-10.6M
Quant / Vol
risk profile
Volatility
206%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
29.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 20, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−35%
Bearish
Price vs 50-day avg
−5%
Bearish
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -60.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $0
Now $0 · 19%
52-wk high $0
vs 200-day avg -35%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BPTH
this stock
Bio-Path Holdings, Inc.
|
$2.01M | -33.3% | -100.0% | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BPTH | -20.0% | +33.3% | -20.0% | -20.0% | -33.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -19.8% | +32.5% | -27.4% | -19.8% | -42.6% |